Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble Protrusion Array Device (PAD)

Molecular Therapy

Volumn 18, Issue 9, 2010, Pages 1667-1674

  Gonzalez Gonzalez, Emilio ^a   Speaker, Tycho J ^b   Hickerson, Robyn P ^b   Spitler, Ryan ^a,b   Flores, Manuel A ^b   Leake, Devin ^c   Contag, Christopher H ^a   Kaspar, Roger L ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TransDerm   (United States)

^c Thermo Fisher Scientific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; PLASMID DNA; POLYVINYL ALCOHOL; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; EAR; EPIDERMIS; FEMALE; FOOT PAD; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; IN VIVO STUDY; MOUSE; NONHUMAN; PROTRUSION ARRAY DEVICE; REPORTER GENE; RNA ANALYSIS; SKIN DISEASE; SKIN PENETRATION; STRATUM CORNEUM; TRANSGENIC MOUSE;

EID: 77956263271     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.126     Document Type: Article

References (30)

1. Uitto, J and Pulkkinen, L (2000). The genodermatoses: candidate diseases for gene therapy. Hum Gene Ther 11: 2267-2275.
2. Smith, FJD, Kaspar, RL, Schwartz, ME, McLean, WHI and Leachman, SA (2006). Pachyonychia congenita. GeneReviews .
3. Leachman, SA, Kaspar, RL, Fleckman, P, Florell, SR, Smith, FJ, McLean, WH et al. (2005). Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc 10: 3-17.
4. Leachman, SA, Hickerson, RP, Hull, PR, Smith, FJ, Milstone, LM, Lane, EB et al. (2008). Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci 51: 151-157.
5. Hickerson, RP, Smith, FJ, Reeves, RE, Contag, CH, Leake, D, Leachman, SA et al. (2008). Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol 128: 594-605.
6. Leachman, SA, Hickerson, RP, Schwartz, ME, Bullough, EE, Hutcherson, SL, Boucher, KM et al. (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 18: 442-446.
7. Barry, BW (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 14: 101-114.
8. Brown, MB, Martin, GP, Jones, SA and Akomeah, FK (2006). Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 13: 175-187.
9. Gonzalez-Gonzalez, E, Ra, H, Hickerson, RP, Wang, Q, Piyawattanametha, W, Mandella, MJ et al. (2009). siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model. Gene Ther 16: 963-972.
10. Arora, A, Prausnitz, MR and Mitragotri, S (2008). Micro-scale devices for transdermal drug delivery. Int J Pharm 364: 227-236.
11. Gill, HS, Denson, DD, Burris, BA and Prausnitz, MR (2008). Effect of microneedle design on pain in human volunteers. Clin J Pain 24: 585-594.
12. Hickerson, RP, Vlassov, AV, Wang, Q, Leake, D, Ilves, H, Gonzalez-Gonzalez, E et al. (2008). Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 18: 345-354.
13. Schwarz, DS, Ding, H, Kennington, L, Moore, JT, Schelter, J, Burchard, J et al. (2006). Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2: e140.
14. Brummelkamp, TR, Bernards, R and Agami, R (2002). Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243-247.
15. Ding, H, Schwarz, DS, Keene, A, Affar, el B, Fenton, L, Xia, X et al. (2003). Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2: 209-217.
16. Dykxhoorn, DM, Schlehuber, LD, London, IM and Lieberman, J (2006). Determinants of specific RNA interference-mediated silencing of human βglobin alleles differing by a single nucleotide polymorphism. Proc Natl Acad Sci USA 103: 5953-5958.
17. Smith, FJ, Hickerson, RP, Sayers, JM, Reeves, RE, Contag, CH, Leake, D et al. (2008). Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol 128: 50-58.
18. Hengge, UR, Walker, PS and Vogel, JC (1996). Expression of naked DNA in human, pig, and mouse skin. J Clin Invest 97: 2911-2916.
19. Lee, JW, Park, JH and Prausnitz, MR (2008). Dissolving microneedles for transdermal drug delivery. Biomaterials 29: 2113-2124.
20. Kaspar, RL, McLean, WH and Schwartz, ME (2009). Achieving successful delivery of nucleic acids to skin: 6th Annual Meeting of the International Pachyonychia Congenita Consortium. J Invest Dermatol 129: 2085-2087.
21. Gupta, AK, Eshraghi, Y, Gliniak, C and Gosain, AK (2010). Nonviral transfection of mouse calvarial organ in vitro using Accell-modified siRNA. Plast Reconstr Surg 125: 494-501.
22. Difeo, A, Huang, F, Sangodkar, J, Terzo, EA, Leake, D, Narla, G et al. (2009). KLF6- SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Res 69: 4733-4741.
23. Coulman, SA, Barrow, D, Anstey, A, Gateley, C, Morrissey, A, Wilke, N et al. (2006). Minimally invasive cutaneous delivery of macromolecules and plasmid DNA via microneedles. Curr Drug Deliv 3: 65-75.
24. Birchall, J, Coulman, S, Pearton, M, Allender, C, Brain, K, Anstey, A et al. (2005). Cutaneous DNA delivery and gene expression in ex vivo human skin explants via wet-etch micro-fabricated micro-needles. J Drug Target 13: 415-421.
25. Pearton, M, Allender, C, Brain, K, Anstey, A, Gateley, C, Wilke, N et al. (2008). Gene delivery to the epidermal cells of human skin explants using microfabricated microneedles and hydrogel formulations. Pharm Res 25: 407-416.
26. Ng, KW, Pearton, M, Coulman, S, Anstey, A, Gateley, C, Morrissey, A et al. (2009). Development of an ex vivo human skin model for intradermal vaccination: tissue viability and Langerhans cell behaviour. Vaccine 27: 5948-5955.
27. Birchall, J, Coulman, S, Anstey, A, Gateley, C, Sweetland, H, Gershonowitz, A et al. (2006). Cutaneous gene expression of plasmid DNA in excised human skin following delivery via microchannels created by radio frequency ablation. Int J Pharm 312: 15-23.
28. González-González, E, Ra, H, Spitler, R, Hickerson, RP, Contag, CH and Kaspar, RL (2010). Increased interstitial pressure improves nucleic acid delivery to skin enabling a comparative analysis of constitutive promoters. Gene Ther (epub ahead of print).
29. Geusens, B, Sanders, N, Prow, T, Van Gele, M and Lambert, J (2009). Cutaneous short-interfering RNA therapy. Expert Opin Drug Deliv 6: 1333-1349.
30. Contag, CH and Bachmann, MH (2002). Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 4: 235-260.